Effects of phenylpropanolamine on withdrawal symptoms
- PMID: 7675954
- DOI: 10.1007/BF02246058
Effects of phenylpropanolamine on withdrawal symptoms
Abstract
A prior report (Klesges et al. 1990) suggested that phenylpropanolamine (PPA) was successful in reducing the smoking withdrawal symptom of weight gain in a sample of women. The current investigation evaluates whether the effects of phenylpropanolamine (PPA; up to 10/day PPA gums) on withdrawal symptoms associated with smoking cessation are specific to weight and weight-related symptoms or whether PPA alleviates withdrawal in general. One hundred and seven adult smokers (56 men, 51 women) were randomly assigned, in this double-blind trial, to chew either 8.33 mg phenylpropanolamine gum or a placebo gum. Subjects were then aided to quit smoking for 4 weeks. PPA did not enhance cessation rates. Results from the 47 subjects who successfully quit smoking indicated that postcessation weight gain and ratings of hunger were significantly reduced in both men and women for those assigned to the PPA group relative to the placebo group. Overall, no effects of PPA relative to placebo were observed for other smoking-related withdrawal symptoms. Thus, although PPA appears to reduce weight gain and alleviate weight-related symptoms, no effects on other withdrawal symptoms were observed. Future research directions are suggested.
Similar articles
-
The effects of phenylpropanolamine on dietary intake, physical activity, and body weight after smoking cessation.Clin Pharmacol Ther. 1990 Jun;47(6):747-54. doi: 10.1038/clpt.1990.103. Clin Pharmacol Ther. 1990. PMID: 2357868 Clinical Trial.
-
A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women.Addict Behav. 2005 Jan;30(1):61-75. doi: 10.1016/j.addbeh.2004.04.013. Addict Behav. 2005. PMID: 15561449 Clinical Trial.
-
Use of phenylpropanolamine to reduce nicotine cessation induced weight gain in rats.Psychopharmacology (Berl). 1992;108(4):501-6. doi: 10.1007/BF02247428. Psychopharmacology (Berl). 1992. PMID: 1410166
-
A review of the physiological bases of the anorexic action of phenylpropanolamine (d,1-norephedrine).Neurosci Biobehav Rev. 1990 Fall;14(3):339-55. doi: 10.1016/s0149-7634(05)80043-0. Neurosci Biobehav Rev. 1990. PMID: 2234611 Review.
-
Smoking, body weight, and their effects on smoking behavior: a comprehensive review of the literature.Psychol Bull. 1989 Sep;106(2):204-30. doi: 10.1037/0033-2909.106.2.204. Psychol Bull. 1989. PMID: 2678202 Review.
Cited by
-
Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h.Psychopharmacology (Berl). 2005 Nov;183(1):1-12. doi: 10.1007/s00213-005-0145-x. Epub 2005 Oct 22. Psychopharmacology (Berl). 2005. PMID: 16160876 Clinical Trial.
-
Prevalence and correlates of initiation of smoking behavior among preteen black and white children.J Natl Med Assoc. 2004 Feb;96(2):200-8. J Natl Med Assoc. 2004. PMID: 14977279 Free PMC article.
-
Weight gain in smokers after quitting cigarettes: meta-analysis.BMJ. 2012 Jul 10;345:e4439. doi: 10.1136/bmj.e4439. BMJ. 2012. PMID: 22782848 Free PMC article.
-
Interventions for preventing weight gain after smoking cessation.Cochrane Database Syst Rev. 2021 Oct 6;10(10):CD006219. doi: 10.1002/14651858.CD006219.pub4. Cochrane Database Syst Rev. 2021. PMID: 34611902 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical